Investing.com - Alx Oncology reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Alx Oncology announced earnings per share of $-0.87 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.81 on revenue of $0.00.
Alx Oncology shares are down 48.09% from the beginning of the year and are trading at $12.50 , down-from-52-week-high.
Alx Oncology follows other major Healthcare sector earnings this month
Alx Oncology's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar